List of Excipients in Branded Drug DIMENHYDRINATE

Generic Drugs Containing DIMENHYDRINATE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	dimenhydrinate	63323-366	BENZYL ALCOHOL
Fresenius Kabi USA LLC	dimenhydrinate	63323-366	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	dimenhydrinate	63323-366	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in DIMENHYDRINATE?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	HYDROCHLORIC ACID
1	PROPYLENE GLYCOL

Dimenhydrinate Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Dimenhydrinate is a mature, low-cost OTC antiemetic with limited API differentiation. The strongest commercial opportunities are formulation-led: pediatric liquids, sugar-free and dye-free products, chewable tablets, orally disintegrating tablets, rapid-dissolution products, and travel-focused packaging. Excipient selection should prioritize dose uniformity, taste masking, moisture control, tablet robustness, preservative performance, and compatibility with OTC labeling requirements.

What is dimenhydrinate and where is it used?

Dimenhydrinate is an ethanolamine antihistamine used primarily for the prevention and treatment of motion sickness. It is a salt combination of diphenhydramine and 8-chlorotheophylline. The drug is marketed in tablets, chewable tablets, liquids, and other dosage forms, most commonly at a 50 mg adult dose.

U.S. OTC labeling generally provides the following dosing framework for motion sickness products:

Population	Typical labeled dose
Adults and children 12 years and older	50-100 mg every 4-6 hours
Children 6 to under 12 years	25-50 mg every 6-8 hours
Children 2 to under 6 years	12.5-25 mg every 6-8 hours
Maximum daily dose	400 mg for adults and older children

The applicable product category is governed by the FDA OTC antiemetic framework in 21 C.F.R. Part 336 and the product’s specific labeling. Dimenhydrinate causes drowsiness in many users, which limits opportunities for positioning around daytime use but supports clear labeling and differentiated packaging.[1]

Which excipients are suitable for dimenhydrinate tablets?

Immediate-release tablets are the lowest-risk and most commercially established platform. The principal formulation challenge is balancing mechanical strength with rapid disintegration at a relatively high active load.

Recommended immediate-release excipient platform

Function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Controls tablet size, density, and compressibility
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Taste modifier	Mannitol, flavors, sweeteners, film coating	Reduces bitterness in chewable or partially dissolving products
Coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide where permitted	Improves swallowability, appearance, and handling

A direct-compression formulation using microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide, and magnesium stearate can support a compact manufacturing process. Wet granulation may be preferable when the selected dose, particle-size distribution, or flow properties produce poor content uniformity.

Dimenhydrinate products should be evaluated for segregation because the active ingredient and excipient fractions may differ substantially in density and particle size. Blend uniformity, tablet-to-tablet assay, friability, dissolution, and weight variation are critical development controls.

What excipients are best for dimenhydrinate chewable tablets?

Chewable tablets offer one of the clearest commercial opportunities because the format reduces the need for water and supports travel use. The main technical risk is taste. Dimenhydrinate has an unpleasant medicinal taste that may remain noticeable if the tablet is chewed slowly.

A typical chewable platform can use mannitol as the primary diluent, with xylitol or sorbitol for mouthfeel and sweetness. Sucralose, aspartame, acesulfame potassium, or saccharin may be used depending on the target market and labeling strategy. Flavor systems should be screened in the finished matrix rather than evaluated only in aqueous solution.

Key development controls include:

• Taste masking over the full labeled shelf life.
• Resistance to capping and lamination.
• Sufficient hardness without an excessively chalky texture.
• Low moisture uptake.
• Acceptable aftertaste at the maximum labeled dose.
• Compatibility with mint, fruit, or mixed-flavor systems.
• Absence of excessive laxation from high polyol loading.

Mannitol is attractive for premium chewables because it provides a cooling sensation and relatively clean mouthfeel. Xylitol can support sugar-free positioning but may require careful control of hygroscopicity and gastrointestinal tolerance. Sorbitol can reduce cost but may produce a softer, more hygroscopic tablet.

How should a dimenhydrinate oral liquid be formulated?

Oral liquid products can address children, older adults, and consumers who cannot swallow tablets. They also create opportunities for sugar-free, alcohol-free, dye-free, and unit-dose products.

The formulation strategy depends on whether dimenhydrinate is fully dissolved, partially solubilized, or presented as a suspension. A liquid solution requires control of pH, ionic strength, solubility, preservative efficacy, and flavor stability. A suspension requires particle-size control, wetting, sedimentation management, redispersibility, and dose uniformity.

Candidate liquid excipients

Formulation function	Candidate excipients
Vehicle	Purified water, glycerin, sorbitol solution, polyethylene glycol
Sweetener	Sucrose, sucralose, sodium saccharin, xylitol
Buffer	Citrate or phosphate systems, subject to compatibility testing
Preservative	Sodium benzoate, potassium sorbate, or other permitted systems
Suspending agent	Xanthan gum, microcrystalline cellulose with carboxymethylcellulose, sodium carboxymethylcellulose
Wetting agent	Polysorbate 80 or other suitable surfactant
Flavor	Fruit, mint, or neutral masking systems
Antioxidant or chelator	Only where justified by stability data

Preservative efficacy testing, microbial limits, container-closure compatibility, and in-use stability are central to the liquid business case. Multi-dose bottles create dosing and contamination risks. Unit-dose cups or stick packs can command a higher price and improve portability, but packaging costs rise.

A pediatric liquid should avoid unnecessary alcohol and should be evaluated for sugar-free and dye-free claims. The label must remain consistent with FDA OTC requirements and age-based dosing instructions. The product should not imply that a formulation is safer for children solely because it is liquid.

What formulation approaches can improve dimenhydrinate taste and onset?

Several formulation concepts can create differentiation without changing the active ingredient:

Orally disintegrating tablets

An orally disintegrating tablet can target consumers who need administration without water. Suitable excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and directly compressible polyols.

The primary risks are taste exposure, tablet friability, moisture sensitivity, and dose uniformity. A rapidly disintegrating tablet does not necessarily produce faster systemic absorption than a conventional tablet. Any onset claim requires comparative clinical or pharmacokinetic support.

Taste-masked multiparticulates

Coated particles or granules can reduce direct contact between dimenhydrinate and taste receptors. The approach increases process complexity and may affect dissolution. Coating polymers, plasticizers, anti-tacking agents, and seal coats must be selected to avoid delayed release unless delayed release is intended and supported.

Rapid-dissolution film or thin oral dosage form

A film could provide portability and water-free administration. It would require a high drug-loading strategy, uniform casting, acceptable tensile strength, rapid disintegration, and reliable dose content across the web. The format is technically more difficult than a tablet because the active ingredient may dominate film thickness and taste.

Effervescent or soluble powder

A sachet or tablet dissolved in water could support travel and hydration-oriented packaging. Acid-base systems must be tested for moisture sensitivity, chemical stability, and palatability. The dosage form also introduces a larger packaging footprint and a need for clear preparation instructions.

What excipient risks are most important for dimenhydrinate?

The major risks are formulation and manufacturing risks rather than known API-patent barriers.

Risk	Likely impact	Mitigation
Bitterness	Poor adherence and repeat purchase	Taste masking, flavor screening, coating, lower-exposure dosage forms
Moisture sensitivity	Loss of tablet strength or stability	Desiccant packaging, high-barrier blisters, moisture studies
Blend segregation	Assay variability	Particle engineering, ordered mixing, validated blending
Over-lubrication	Slow dissolution and weak tablets	Controlled lubricant addition and mixing time
Preservative failure	Microbial risk in liquids	Preservative efficacy testing and packaging controls
Polyol loading	Gastrointestinal intolerance	Limit polyol concentration and validate labeling
Suspension settling	Inaccurate pediatric dosing	Rheology control, redispersibility testing, dosing-device studies
Flavor instability	Loss of consumer acceptability	Long-term and accelerated flavor compatibility testing
Child-resistant packaging	Reduced convenience	Pair compliance packaging with unit-dose or senior-friendly options where appropriate

The FDA Inactive Ingredient Database is a useful screening tool for prior use of excipients in approved drug products, but it does not replace product-specific safety, quality, or compatibility studies.[2]

What FDA regulatory pathway applies to dimenhydrinate products?

Dimenhydrinate OTC products can be developed under the applicable FDA OTC monograph framework when the active ingredient, indication, dosage, route, labeling, and formulation comply with current requirements. A product that falls outside the monograph may require an FDA application or another legally supported pathway.

The regulatory workstream should include:

1. Confirmation of the current OTC monograph or final order requirements.
2. Verification of active concentration and age-specific dosing.
3. Review of inactive ingredients for route, dosage form, and population suitability.
4. Stability, dissolution, assay, content uniformity, and microbial testing.
5. Label review for drowsiness, alcohol, sedatives, driving, pregnancy, and age restrictions.
6. Container-closure and child-resistant packaging assessment.
7. Manufacturing-process validation and complaint surveillance.

The FDA OTC Monograph Database and electronic Code of Federal Regulations should be treated as the primary sources for current regulatory status.[1,3]

What is the Orange Book status of dimenhydrinate?

The Orange Book principally covers FDA-approved prescription and certain approved nonprescription drug applications. Many OTC monograph products are not listed in the same way as prescription products with approved NDAs. As a result, an OTC dimenhydrinate product should not be analyzed as though it has a standard Orange Book patent listing and ANDA pathway.

Paragraph IV litigation is generally associated with an ANDA applicant challenging patents listed for an approved reference drug. For a monograph-compliant OTC dimenhydrinate product, the relevant competitive issues are more likely to involve regulatory compliance, trademarks, trade dress, formulation patents, and manufacturing know-how than a conventional Paragraph IV challenge.

A commercial diligence review should separate:

• API and active-ingredient rights.
• Prescription or NDA-based formulation rights.
• OTC monograph compliance.
• Brand trademarks and packaging rights.
• Private-label supply agreements.
• Formulation or device patents covering a particular product presentation.

How strong is the dimenhydrinate patent estate?

Dimenhydrinate is an old, widely marketed active ingredient. The basic active-ingredient opportunity is therefore weak from an exclusivity perspective. The economic value is more likely to reside in brand recognition, distribution, formulation execution, packaging, and retailer access.

Potentially protectable areas include:

Asset	Relative commercial relevance
New taste-masking system	Moderate if measurable consumer or stability benefit exists
Orally disintegrating formulation	Moderate, subject to claim breadth and prior art
Pediatric liquid or suspension	Low to moderate unless technically differentiated
Unit-dose travel package	Usually trademark, design, or trade-secret value rather than strong composition claims
Combination product	Depends on active ingredients, indication, and regulatory pathway
Manufacturing process	Can provide trade-secret value even where patent protection is limited
Brand and trade dress	Often more durable commercially than formulation exclusivity

No generic-launch delay should be assumed from the existence of a new formulation patent. A competitor may design around excipient ratios, coating materials, manufacturing steps, or packaging claims. Patent strength depends on claim scope, written description, enablement, prosecution history, prior art, and enforceability in the target jurisdiction.

Which companies and products compete with dimenhydrinate?

Competition comes from both branded and private-label products. Dramamine is the best-known U.S. consumer brand associated with dimenhydrinate, while store brands compete primarily on price. Other motion-sickness products include meclizine, scopolamine transdermal products, and non-drug alternatives.

Product category	Competitive advantage	Limitation
Dimenhydrinate tablet	Low cost, broad familiarity	Drowsiness and frequent dosing
Dimenhydrinate chewable	Portable, no water required	Taste and texture constraints
Dimenhydrinate liquid	Pediatric and swallowing convenience	Packaging and preservative burden
Meclizine	Often positioned for less frequent dosing	Different active ingredient and labeling
Scopolamine patch	Extended-duration delivery	Prescription status and anticholinergic risks
Non-drug bands or devices	No active-drug exposure	Variable consumer acceptance and evidence base

A manufacturer can compete without owning a novel API by delivering better taste, easier dosing, more convenient packaging, or stronger retail execution.

What commercial opportunities exist for dimenhydrinate excipient innovation?

The most attractive opportunities are incremental and channel-specific.

Pediatric and family products

A sugar-free, alcohol-free, dye-free liquid with a reliable dosing syringe can target caregivers. A 12.5 mg or 25 mg dose presentation may improve dosing accuracy, provided the product complies with applicable labeling and manufacturing requirements.

Travel-oriented products

Blister packs, individually wrapped chewables, stick packs, and compact kits can support airports, pharmacies, convenience stores, cruise operators, and online travel retailers. Packaging must preserve moisture-sensitive tablets and support child-resistant requirements where applicable.

Premium chewables

Mannitol-based or low-sugar chewables with improved flavor and reduced chalkiness can command a higher retail price than standard tablets. Sensory testing is essential because the principal consumer benefit is experiential.

Senior and dysphagia products

ODTs and easy-open but compliant packaging can serve older users and consumers with swallowing difficulty. The formulation must avoid excessive friability and maintain dose integrity during transport.

Private-label and contract manufacturing

Retailers may prefer turnkey products with established excipient systems, validated packaging, and flexible flavor or color options. A manufacturer can create value through low minimum order quantities, rapid scale-up, and multiple dosage forms using one active supply chain.

What geographic opportunities exist for dimenhydrinate products?

Dimenhydrinate is sold in multiple jurisdictions, but allowable dosage forms, age restrictions, labeling, excipients, and combination products vary by country. A global strategy should not assume that a U.S. OTC monograph product can be transferred directly to Europe, Canada, Asia-Pacific, or Latin America.

The most transferable assets are:

• A stable immediate-release tablet platform.
• A sugar-free oral liquid.
• A chewable formulation with scalable flavor systems.
• High-barrier blister packaging.
• A dossier-supported excipient justification.
• Manufacturing processes that use broadly accepted compendial excipients.

Geographic expansion is constrained by local monographs, national registrations, permitted colors and preservatives, pediatric requirements, and trademark availability. The commercial advantage of a global excipient platform comes from reducing site-specific reformulation rather than eliminating local regulatory work.

When does dimenhydrinate lose exclusivity?

Dimenhydrinate has no meaningful new-molecule exclusivity horizon in the conventional U.S. sense. Its commercial life is already driven by OTC status, brands, formulation execution, and distribution. A newly developed product may obtain limited protection through formulation, process, packaging, trademark, or design rights, but the active ingredient itself should not be treated as an exclusivity asset.

Generic and private-label entry risks are high for conventional tablets. They are lower, but not eliminated, for products with validated taste masking, specialized packaging, proprietary multiparticulate processing, or strong retail placement.

Key Takeaways

• Dimenhydrinate is a mature OTC active ingredient with limited API-level exclusivity.
• Immediate-release tablets remain the lowest-cost commercial platform.
• Chewables, ODTs, pediatric liquids, and unit-dose travel products offer the strongest formulation-led opportunities.
• Mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, povidone, and standard flavor systems are practical starting points, subject to product-specific testing.
• Taste masking is the central technical and consumer challenge.
• Liquid products require strong control of preservative efficacy, microbial quality, dosing accuracy, and container compatibility.
• Orange Book and Paragraph IV analysis is less central for monograph OTC products than for approved prescription products.
• Competitive advantage is more likely to come from excipient execution, packaging, brand, and distribution than from the dimenhydrinate molecule.
• Formulation patents may protect differentiated products, but conventional tablets face substantial generic and private-label competition.
• The highest-value commercial concepts are sugar-free pediatric liquids, premium chewables, rapid-disintegration products, and travel-ready unit-dose formats.

FAQs about dimenhydrinate excipient strategy

Can dimenhydrinate be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, and selected polyols can replace lactose. The replacement affects compressibility, dissolution, hardness, and mouthfeel and must be revalidated.

Is dimenhydrinate suitable for a sugar-free chewable?

Yes. Mannitol, xylitol, sorbitol, sucralose, and other permitted sweeteners can support a sugar-free product. Polyol concentration requires gastrointestinal-tolerance assessment and appropriate labeling.

What packaging is best for moisture-sensitive dimenhydrinate tablets?

High-barrier alu-alu blisters or appropriately selected HDPE bottles with desiccant protection are leading options. The final choice depends on stability data, unit-dose requirements, cost, and child-resistant packaging needs.

Can dimenhydrinate be combined with caffeine?

A combination may be technically feasible, but it requires separate regulatory, labeling, compatibility, dose, and safety analysis. The combination should not be treated as automatically covered by the monograph framework for dimenhydrinate alone.

Does a new dimenhydrinate formulation automatically receive market exclusivity?

No. A new product may obtain protection through patents, trademarks, trade dress, regulatory approvals, or trade secrets, but the old active ingredient does not create new exclusivity for a conventional formulation.

References

1. Electronic Code of Federal Regulations. (2025). 21 C.F.R. Part 336: Antiemetic drug products for over-the-counter human use. https://www.ecfr.gov/

2. U.S. Food and Drug Administration. (2025). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

3. U.S. Food and Drug Administration. (2025). OTC Monograph Database. https://www.accessdata.fda.gov/scripts/cder/otc/

4. National Library of Medicine. (2025). Dimenhydrinate. PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2025). Drug products marketed in the United States: Drugs@FDA and Orange Book resources. https://www.fda.gov/drugs/atf-drugs-drug-approvals-and-databases